



Dr Ho Han Kiat
Assistant Professor
Department of Pharmacy
Faculty of Science, NUS
18 Science Drive 4
Block S4, #03-03
Email: phahohk@nus.edu.sg



MAJOR RESEARCH INTERESTS

- Tyrosine kinase inhibitors
- Liver pathologies
- Drug-induced toxicities
-

SELECTED PUBLICATIONS (15 representative ones since 2009)

1. **Ho HK (Corresponding author)**, Pok S, Streit SS, Ruhe JE, Hart S, Loo HL, Lim KS, Aung MO, Lim SG, Ullrich A. *J Hepatology*, 50, 118-127 (2009). FGFR4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
2. Saha S, New LS, **Ho HK**, Chui WK, Chan ECY. *Tox Letters*, 192, 141-149 (2010). Investigation of the role of thiazolidinedione ring of troglitazone in inducing hepatotoxicity
3. Roidl A, Foo P, Mann C, Bechtold S, Berger HJ, Streit S, Ruhe JE, Hart S, Ullrich A, **Ho HK (Corresponding author)**. *Oncogene*, 29, 1543-1552 (2010). The FGFR4 Y367C Mutant is a Dominant Oncogene in MDA-MD453 Breast Cancer Cells.
4. Saha S, New LS, **Ho HK**, Chui WK, Chan ECY. *Tox Letters*, 195(2-3), 135-141 (2010). Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes.
5. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, **Ho HK** and Chan CYE. *Mol Pharmacol*, 78, 693-703 (2010). Mechanism-based inactivation of Cytochrome P450 3A4 by lapatinib.
6. Nayak T, Li J, Phua LC, **Ho HK**, Ren Y, Pastorin G. *ACS Nano*, 4(12), 7717-25 (2010). Thin films of functionalized multi-walled carbon nanotubes as suitable scaffold materials for stem cells proliferation and bone formation.
7. Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, **Ho HK**, Chan A. *Breast Cancer Res Treat*, 133(2), 703-711 (2012). Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence.
8. Poh W, Wong W, Ong H, Aung MO, Lim SG, Chua BT, **Ho HK (Corresponding author)**. *Mol Cancer*, 11:14 (2012). Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
9. Chan EC, New LS, Chua TB, Yap CW, **Ho HK**, Nelson SD. *Drug Metab Disp*, 40(7), 1414-1422 (2012). Interaction of lapatinib with cytochrome P450 3A5.
10. Zhao C, Tan A, Pastorin G, **Ho HK (Corresponding author)**. *Biotech Adv*, 31(5), 654-68 (2012). Nanomaterial scaffolds for stem cell differentiation and proliferation in tissue engineering.
11. Saha S, Chan DS, Lee CY, Wong W, Yap CW, Chui WK, Chan EC, **Ho HK (Corresponding author)**. *Eur J Pharmacol* 697(1-3), 13-23 (2012). Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.

12. Teo YL, **Ho HK**, Chan A. *Cancer Treat Rev* 39(2), 199-206 (2013). Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis.
13. Phua LC, Mal M, Koh PK, Cheah PY, Chan EC, **Ho HK (Corresponding author)**. *Cancer Chemother Pharmacol* 71(3):817-823 (2013). Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy.
14. **Ho HK (Corresponding author)**, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, Breza N, Greff Z, Horváth Z; Pató J, Szabadkai I, Szokol B, Baska F, Órfi L, Ullrich A, Kéri G, and Chua BT. *Curr Med Chem*, 20:1203-17 (2013). Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
15. **Ho HK (Corresponding author)**, Yeo AHL, Kang TS, Chua BT. *Drug Discover Today*, e-published (2013). Current strategies in inhibiting FGFR activities for clinical applications: Opportunities, challenges and toxicological considerations.